The Blood Thinner Pradaxa and Serious Bleeding and Hemorrhaging
The FDA Is Evaluating Risk of Serious Bleeding Episodes with Prescription Drug Pradaxa. Pradaxa (dabigatran etexilate) is an oral blood thinner that was approved by the US FDA in October 2010. Pradaxa is in the class of anticoagulant (anti-clotting) blood thinners called “direct thrombin inhibitors”.
The drug is used to prevent serious blood clots in patients with atrial fibrillation. Atrial fibrillation is a heart condition in which the upper chambers of the heart (atria) fail to contract fully causing potential stagnant blood and clot formation.
Patients with atrial fibrillation are often candidates for long term anticoagulation. Prior to the release of Pradaxa these patients were either treated with oral Coumadin, low molecular weight heparin, or less effective antiplatelet agents such as aspirin.
Recently, studies have shown that patients on Pradaxa have a 33% higher risk of heart attack when compared to previously prescribed medications. The FDA is currently investigating an unusually high number of reports of serious bleeding linked to Pradaxa’s use.
Some of Pradaxa’s side effects include:
- Internal bleeding;
- Gastrointestinal bleeding;
- Brain hemorrhage; and
- Kidney bleeding and death.
ABOUT THE AUTHOR: Rudy Milgiore
With over three decades of experience, the law office of Rudolph F.X. Migliore, P.C., is well positioned to help those who have been harmed by Pradaxa. Our firm works with nationally recognized co-counsel to reach major verdicts and settlements.
Copyright Rudolph F. X. Migliore, PC
More information about Rudolph F. X. Migliore, PC
Disclaimer: While every effort has been made to ensure the accuracy of this publication, it is not intended to provide legal advice as individual situations will differ and should be discussed with an expert and/or lawyer. For specific technical or legal advice on the information provided and related topics, please contact the author.